Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antihistamine |
| gptkbp:ATCCode |
R06AC01
|
| gptkbp:CASNumber |
91-84-9
|
| gptkbp:chemicalFormula |
C16H21N3
|
| gptkbp:developedBy |
gptkb:Daniel_Bovet
|
| gptkbp:discoveredIn |
1937
|
| gptkbp:drugClass |
ethylenediamine antihistamines
|
| gptkbp:hasSMILES |
CN(C)CCN(CC1=CC=CC=N1)CC2=CC=CC=N2
|
| gptkbp:hasUNII |
Q8V5M8C0D9
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pyribenzamine
|
| gptkbp:IUPACName |
N,N-dimethyl-N'-pyridin-2-yl-N'-(2-pyridyl)ethane-1,2-diamine
|
| gptkbp:legalStatus |
prescription only (in some countries)
|
| gptkbp:marketedAs |
Neo-Antergan
|
| gptkbp:molecularWeight |
255.36 g/mol
|
| gptkbp:PubChem_CID |
4787
CHEMBL1201272 |
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:sideEffect |
drowsiness
|
| gptkbp:usedFor |
treatment of allergies
|
| gptkbp:bfsParent |
gptkb:CIBA
|
| gptkbp:bfsLayer |
6
|